Literature DB >> 16236621

Recurrent seizure and sustained encephalopathy associated with dimethylsulfoxide-preserved stem cell infusion.

Deborah Bauwens1, Philippe Hantson, Pierre-François Laterre, Lucienne Michaux, Dominique Latinne, Marianne De Tourtchaninoff, Guy Cosnard, Danielle Hernalsteen.   

Abstract

We report the case of a patient who received two infusions of dimethylsulfoxide (DMSO) cryopreserved autologous peripheral blood progenitor cells (PBPCs) after myeloablative chemotherapy for a relapsing lymphoma. A 49-year-old man presented an episode of tonic-clonic seizure over a few minutes after the start of each infusion and developed a profound and sustained but reversible encephalopathy with coma after the second infusion. The patient's neurological condition correlated well with the electrophysiological findings (electroencephalogram and multimodality evoked potentials) and, to a lesser extent, with the radiological abnormalities (magnetic resonance imaging). Severe but reversible neurological complications may occur with the infusion of PBPCs cryopreserved with DMSO.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236621     DOI: 10.1080/10428190500235611

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  16 in total

Review 1.  Reversible posterior leukoencephalopathy syndrome in cancer.

Authors:  Christopher Vaughn; Louann Zhang; David Schiff
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

2.  Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftment.

Authors:  Nandita Khera; Jack Jinneman; Barry E Storer; Shelly Heimfeld; Megan M O'Meara; Thomas R Chauncey; Stephanie J Lee; Michael Linenberger
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-15       Impact factor: 5.742

Review 3.  Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion.

Authors:  Z Shu; S Heimfeld; D Gao
Journal:  Bone Marrow Transplant       Date:  2013-09-30       Impact factor: 5.483

Review 4.  The double-edged sword: Neurotoxicity of chemotherapy.

Authors:  Rajiv S Magge; Lisa M DeAngelis
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

Review 5.  Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy.

Authors:  Xue Yao; Sandro Matosevic
Journal:  BioDrugs       Date:  2021-08-24       Impact factor: 5.807

6.  Sugar-Assisted Cryopreservation of Stem Cell-Laden Gellan Gum-Collagen Interpenetrating Network Hydrogels.

Authors:  Jian Yao Ng; Kee Ying Fremi Tan; Pui Lai Rachel Ee
Journal:  Biomacromolecules       Date:  2022-06-08       Impact factor: 6.978

7.  Transient loss of consciousness in pediatric recipients of dimethylsulfoxide (DMSO)-cryopreserved peripheral blood stem cells independent of morphine co-medication.

Authors:  Paul G Schlegel; Matthias Wölfl; Judith Schick; Beate Winkler; Matthias Eyrich
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

8.  Evaluation of the toxicity of onyx compared with n-butyl 2-cyanoacrylate in the subarachnoid space of a rabbit model: an experimental research.

Authors:  Bulent Bakar; Hakan H Oruckaptan; Burcu D Hazer; Isil Saatci; Pergin Atilla; Kamer Kilic; Sevda F Muftuoglu
Journal:  Neuroradiology       Date:  2009-09-15       Impact factor: 2.804

9.  The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.

Authors:  Jeremy S Abramson; Wen Chen; Przemyslaw Juszczynski; Hidenobu Takahashi; Donna Neuberg; Jeffery L Kutok; Kunihiko Takeyama; Margaret A Shipp
Journal:  Br J Haematol       Date:  2008-11-13       Impact factor: 6.998

10.  Dimethyl sulfoxide damages mitochondrial integrity and membrane potential in cultured astrocytes.

Authors:  Chan Yuan; Junying Gao; Jichao Guo; Lei Bai; Charles Marshall; Zhiyou Cai; Linmei Wang; Ming Xiao
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.